Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia

M R Korte, M J van Heerde, R A de Man, M H G Betjes*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
2 Downloads (Pure)


Mixed-type cryoglobulins are strongly associated with hepatitis C virus (HCV) infection and may lead to vasculitis with renal involvement. The treatment of this condition is antiviral therapy for HCV, but this may be ineffective or not tolerated because of side effects. Alternative strategies such as immunosuppressive drugs and plasmapheresis are of limited use, especially in patients after liver transplantation (LTx). We describe an LTx patient with cryoglobulinaemia-associated glomerulonephritis, who was treated successfully with the B cell depleting monoclonal antibody rituximab.

Original languageEnglish
Pages (from-to)27-30
Number of pages4
JournalNetherlands Journal of Medicine
Issue number1
Publication statusPublished - Jan 2008

Bibliographical note

© 2008 Van Zuiden Communications B.V. All rights reserved.

Research programs

  • EMC MM-04-20-02-A
  • EMC MM-04-39-05


Dive into the research topics of 'Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia'. Together they form a unique fingerprint.

Cite this